Synteract opening a new office, hiring for several positions as demand increases

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/marchmeena29)
(Image: Getty/marchmeena29)

Related tags: Synteract, CRO

Synteract is opening a new office in Swansea, Wales in response to increased demand across its core therapeutic areas for both full-service work and more consultative, standalone projects, says CEO.

Synteract​ CEO Steve Powell said the location – the second largest city in Wales – was chosen for the company’s next office location due to its proximity to multiple universities and “its history as a good location for clinical research professionals.”

The contract research organization (CRO) is interviewing for several positions including clinical data coordinator, statistical programmer, biostatistician, process analyst, among others, and plans to open to the office late in the second quarter of 2019.

The company in 2018 announced the creation of “therapeutic centers of development” ​as it looks to deepen its footprint in the mid-sized CRO market space. These centers include dermatology, neurodegenerative, oncology, pediatrics, and rare/orphan disease. 

Powell told us a main driver of demand for Synteract has come from “this clear delineation of focus on these growing development areas, where Synteract is well positioned to help clients advance the innovative therapies that patients need.”

As part of this commitment, the company in July 2018 acquired​ the specialized dermatology CRO Cu-Tech, and the pediatrics CRO KinderPharm​ in November the same year.

Powell added, “We have seen increased demand in our core therapeutic areas, for both full-service, global work as well as more consultative, standalone projects.”

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more